Colombia

Colombia's relationship with psychoactive plants and fungi is long-standing and rooted in indigenous and mestizo ethnobotanical practice. For millennia, Amazonian and Andean communities in what is now Colombia have used plant-based medicines — notably ayahuasca (yagé), San Pedro (Echinopsis spp.) and a variety of herbal preparations — within ritual and healing contexts. Early 20th-century ethnographers and botanists recorded these traditions episodically, but systematic academic attention to Colombia's psychoactive flora and associated ritual use intensified only in the latter half of the century as ethnobotany and cultural anthropology matured as disciplines.

International developments in psychedelic science set the broader context for Colombian research. The mid-20th-century pharmacological discoveries — most notably Albert Hofmann's identification of LSD's psychoactivity at Sandoz in 1943 — and subsequent international regulatory frameworks shaped national control regimes and research possibilities. Colombia, as a party to the major United Nations drug conventions, adopted narcotics and psychotropic scheduling that constrained commercial and clinical use of many classical psychedelics, while nonetheless allowing limited scientific and ethnographic inquiry under institutional review and licensing.

From the 1990s onwards there has been a steady increase in Colombian academic output touching on psychoactive substances, concentrated in ethnobotany, mycology, pharmacology and public health. Colombian universities and researchers have documented traditional ayahuasca practices in Amazonian communities, characterised the ecology of cacti and fungal species across Andean and Chocó biomes, and begun preliminary neuropharmacological and psychopharmacological studies. Much work has been descriptive and taxonomic, reflecting Colombia's exceptional biodiversity and the priority of cataloguing species and uses before translational clinical programmes could be mounted.

In the 2010s and early 2020s the landscape diversified: private clinical services expanded (notably ketamine for treatment-resistant depression and other off-label uses under existing medical frameworks), international collaborations increased, and interest in regulated clinical trials grew alongside global reinvigoration of psychedelic-assisted therapies. Regulatory and legal ambiguities remain salient in Colombia — indigenous traditional use is widespread and culturally entrenched, but formal clinical research with scheduled substances is regulated tightly and typically requires institutional approvals, import permits and compliance with national narcotics control authorities.